Showing results (331-340 of 457) with videos related to

Sort By:
Pageof 46
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 20, 2024
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomesY Loriot, D P Petrylak, A Rezazadeh Kalebasty, et al.
Future Oncology (London, England)|April 29, 2024
A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancerYohann Loriot, Arash Rezazadeh Kalebasty, Aude Fléchon, et al.
BJU International|June 30, 2018
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programmeUgo De Giorgi, Giacomo Cartenì, Diana Giannarelli, et al.
Oncology|January 17, 2015
Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trialCora N Sternberg, Fabio Calabrò, Sergio Bracarda, et al.
Targeted Oncology|January 7, 2015
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapyMatteo Santoni, Sebastiano Buti, Alessandro Conti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 11, 2019
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with NivolumabUgo De Giorgi, Giuseppe Procopio, Diana Giannarelli, et al.
Molecular Oncology|March 1, 2022
The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapyJohannes C van der Mijn, Kenneth W Eng, Pooja Chandra, et al.
ESMO Open|May 13, 2021
Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohortG Fornarini, S E Rebuzzi, G L Banna, et al.
European Urology|March 24, 2016
The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerChristopher P Evans, Celestia S Higano, Thomas Keane, et al.
European Urology|July 18, 2021
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD StudyCora N Sternberg, Daniel Castellano, Johann de Bono, et al.
Pageof 46